“…Many of these studies were limited by small sample size and identified no significant SNPs. [11][12][13][14][15][16][17][18][19][20][21][22] Among CGAS that identified significant variants, candidate genes were related to drug metabolism (CBR3, 23 UGT1A6, 24,25 and POR 26 ), drug transport (SLC28A3, 25,27 SLC22A17, 28 SLC22A7, 28 ABCC2, 29 ABCC1, [30][31][32] ABCC5, 33 and ABCG2 34 ), iron metabolism (HFE 29,35 ), cell signalling (RAC2, 29,31 NOS3, 33 and PLCE1 36 ), DNA repair (ERCC2, 37 BRCA1, 38 and BRCA2 38 ), splicing regulation (CELF4 24 ), response to oxidative stress (CAT, 39 NCF4, 31,40,41 GSTP1, 42 and CYBA 31,41 ), calcium homeostasis (ATP2B1 36 ), myosin synthesis (MYH7 43 ), and extracellular matrix synthesis (HAS3 24,44 ). Additionally, two exome array analyses identified candidate genes (ETFB 45 and GPR35 46 ) that were significant only when analysed with a gene-based approach.…”